<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR35">
 <label>35.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Dombi</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Baldwin</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Marcus</surname>
    <given-names>LJ</given-names>
   </name>
   <name>
    <surname>Fisher</surname>
    <given-names>MJ</given-names>
   </name>
   <name>
    <surname>Weiss</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Whitcomb</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Martin</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Aschbacher-Smith</surname>
    <given-names>LE</given-names>
   </name>
   <name>
    <surname>Rizvi</surname>
    <given-names>TA</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas</article-title>
  <source>N Engl J Med</source>
  <year>2016</year>
  <volume>375</volume>
  <issue>26</issue>
  <fpage>2550</fpage>
  <lpage>2560</lpage>
  <pub-id pub-id-type="doi">10.1056/NEJMoa1605943</pub-id>
  <?supplied-pmid 28029918?>
  <pub-id pub-id-type="pmid">28029918</pub-id>
 </element-citation>
</ref>
